HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

The approval of CDK4/6 inhibitors has dramatically improved care for the treatment of HR+/HER2– advanced breast cancer, but navigating the rapidly-expanding treatment evidence base is challenging. In this narrative review, we provide best-practice recommendations for the first-line treatment of HR+/...

Descripción completa

Detalles Bibliográficos
Autores principales: Jerzak, Katarzyna J., Bouganim, Nathaniel, Brezden-Masley, Christine, Edwards, Scott, Gelmon, Karen, Henning, Jan-Willem, Hilton, John F., Sehdev, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297170/
https://www.ncbi.nlm.nih.gov/pubmed/37366894
http://dx.doi.org/10.3390/curroncol30060411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297170/
https://www.ncbi.nlm.nih.gov/pubmed/37366894
http://dx.doi.org/10.3390/curroncol30060411

Ejemplares similares